Skip to main content

Decheng Capital LLC

13F filer · CIK 0002010850
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$732MU.S. long equity reported on 13F
Positions141 new · 1 closed
Net flow last quarter-$15.2MBuys minus sells
Top 10 positions weight98.1%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202614 positions
CGONCG Oncology, Inc.$453M61.87%7.22%Not reportedQ1 2024
NUVBNuvation Bio Inc.$147M20.15%7.49%Not reportedQ2 2024
AARDAardvark Therapeutics, Inc.$22.6M3.08%17.90%Not reportedQ1 2025
ACRSAclaris Therapeutics, Inc.$21.4M2.92%2.89%Not reportedQ4 2024
UPBUpstream Bio, Inc.$18.9M2.58%4.98%Not reportedQ4 2024
RCUSArcus Biosciences, Inc.$14.3M1.96%0.37%-2.7%Q4 2023
EQEquillium, Inc.$14.2M1.94%7.01%Not reportedQ4 2023
RVMDRevolution Medicines, Inc.$9.86M1.35%0.02%-43.7%Q3 2024
LYELLyell Immunopharma, Inc.$9.72M1.33%2.96%Not reportedQ4 2024
BYSIBeyondSpring Inc.$6.65M0.91%9.24%Not reportedQ4 2023
ZNTLZentalis Pharmaceuticals, Inc.$6.42M0.88%1.85%Not reportedQ4 2023
NAMSNewAmsterdam Pharma Co N.V.$5.99M0.82%0.15%-45.6%Q2 2024
PYXSPyxis Oncology, Inc.$984K0.13%0.52%Not reportedQ4 2023
TNGXTango Therapeutics, Inc.$625K0.09%0.01%NewQ2 2026
Q1 2026Reported May 13, 202614 positions
CGONCG Oncology, Inc.$431M65.21%7.24%Not reportedQ1 2024
NUVBNuvation Bio Inc.$111M16.84%7.49%-2.4%Q2 2024
UPBUpstream Bio, Inc.$24.5M3.71%5.01%-13.3%Q4 2024
ACRSAclaris Therapeutics, Inc.$15.2M2.29%2.89%Not reportedQ4 2024
AARDAardvark Therapeutics, Inc.$14.8M2.23%17.96%Not reportedQ1 2025
LYELLyell Immunopharma, Inc.$13.9M2.10%2.97%Not reportedQ4 2024
NAMSNewAmsterdam Pharma Co N.V.$10.4M1.57%0.28%-45.1%Q2 2024
RCUSArcus Biosciences, Inc.$10.3M1.56%0.38%-11.8%Q4 2023
RVMDRevolution Medicines, Inc.$9.09M1.37%0.05%-53.3%Q3 2024
EQEquillium, Inc.$8.89M1.34%7.03%Not reportedQ4 2023
BYSIBeyondSpring Inc.$6.23M0.94%9.24%Not reportedQ4 2023
ZNTLZentalis Pharmaceuticals, Inc.$3.1M0.47%1.86%Not reportedQ4 2023
KRYSKrystal Biotech, Inc.$1.89M0.29%0.02%-57.8%Q4 2023
PYXSPyxis Oncology, Inc.$477K0.07%0.52%Not reportedQ4 2023
Q4 2025Reported Feb 12, 202618 positions
CGONCG Oncology, Inc.$265M35.59%7.90%Not reportedQ1 2024
NUVBNuvation Bio Inc.$233M31.31%7.68%Not reportedQ2 2024
UPBUpstream Bio, Inc.$85.3M11.48%5.80%-4.3%Q4 2024
AARDAardvark Therapeutics, Inc.$51.4M6.92%17.96%Not reportedQ1 2025
LYELLyell Immunopharma, Inc.$21.3M2.87%3.26%+16.2%Q4 2024
NAMSNewAmsterdam Pharma Co N.V.$20.8M2.79%0.52%-9.9%Q2 2024
RVMDRevolution Medicines, Inc.$15.9M2.14%0.10%-4.8%Q3 2024
RCUSArcus Biosciences, Inc.$12.9M1.74%0.43%-1.1%Q4 2023
ACRSAclaris Therapeutics, Inc.$12.2M1.64%3.35%Not reportedQ4 2024
EQEquillium, Inc.$6.89M0.93%7.24%Not reportedQ4 2023
BYSIBeyondSpring Inc.$6.2M0.83%9.24%-11.3%Q4 2023
CRNXCrinetics Pharmaceuticals, Inc.$4.32M0.58%0.10%-35.2%Q1 2024
KRYSKrystal Biotech, Inc.$4.27M0.57%0.06%-46.4%Q4 2023
AURAAura Biosciences, Inc.$1.96M0.26%0.57%-30.1%Q4 2023
ZNTLZentalis Pharmaceuticals, Inc.$1.79M0.24%1.92%Not reportedQ4 2023
PYXSPyxis Oncology, Inc.$376K0.05%0.52%Not reportedQ4 2023
FDMT4D Molecular Therapeutics, Inc.$332K0.04%0.08%-52.2%Q1 2024
RZLTRezolute, Inc.$141K0.02%0.06%Not reportedQ2 2025
Q3 2025Reported Nov 14, 202522 positions
CGONCG Oncology, Inc.$257M44.78%8.14%Not reportedQ1 2024
NUVBNuvation Bio Inc.$96.1M16.77%7.87%Not reportedQ2 2024
UPBUpstream Bio, Inc.$61.8M10.78%6.08%Not reportedQ4 2024
AARDAardvark Therapeutics, Inc.$52.1M9.08%18.01%Not reportedQ1 2025
NAMSNewAmsterdam Pharma Co N.V.$18.7M3.26%0.58%-14.7%Q2 2024
MRUSMerus N.V.$17.6M3.06%0.25%-1.4%Q1 2024
RVMDRevolution Medicines, Inc.$9.81M1.71%0.11%-7.1%Q3 2024
LYELLyell Immunopharma, Inc.$9.67M1.69%3.09%Not reportedQ4 2024
BYSIBeyondSpring Inc.$7.76M1.35%10.42%-5.4%Q4 2023
ACRSAclaris Therapeutics, Inc.$7.68M1.34%3.73%Not reportedQ4 2024
RCUSArcus Biosciences, Inc.$7.45M1.30%0.51%+242.3%Q4 2023
EQEquillium, Inc.$6.36M1.11%7.33%Not reportedQ4 2023
CRNXCrinetics Pharmaceuticals, Inc.$5.96M1.04%0.15%Not reportedQ1 2024
KRYSKrystal Biotech, Inc.$5.7M0.99%0.11%-51.1%Q4 2023
AURAAura Biosciences, Inc.$3.19M0.56%0.82%Not reportedQ4 2023
ZNTLZentalis Pharmaceuticals, Inc.$2M0.35%1.83%Not reportedQ4 2023
MLTXMoonLake Immunotherapeutics$1.3M0.23%0.34%Not reportedQ1 2024
FDMT4D Molecular Therapeutics, Inc.$806K0.14%0.20%-61.3%Q1 2024
ILMNIllumina, Inc.$758K0.13%0.01%Not reportedQ4 2023
PYXSPyxis Oncology, Inc.$726K0.13%0.53%Not reportedQ4 2023
GRALGRAIL, Inc.$573K0.10%0.03%Not reportedQ2 2024
RZLTRezolute, Inc.$563K0.10%0.07%Not reportedQ2 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.